Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 334-337, June 2010

Long term follow-up of Parkinson's disease patients with impulse control disorders

  • Melis Sohtaoğlu

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
  • ,
  • Derya Yavuz Demiray

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
  • ,
  • Gülay Kenangil

      Affiliations

    • Department of Neurology, Sisli Etfal Education and Research Hospital, Istanbul, Turkey
  • ,
  • Sibel Özekmekçi

      Affiliations

    • Department of Neurology, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey
    • Corresponding Author InformationCorresponding author. Tel./fax: +90 0212 588 3770.
  • ,
  • Ethem Erginöz

      Affiliations

    • Department of Community Medicine Center, Cerrahpasa Faculty of Medicine, Istanbul University, 34098 Istanbul, Turkey

Received 3 January 2010; received in revised form 8 February 2010; accepted 11 February 2010.

Abstract 

Objective

Impulse control disorders (ICDs) are mainly triggered by dopaminergic therapy in Parkinson's disease (PD). Previously, we failed to identify a relationship between the types of dopaminergic therapy and occurrence of ICDs in 33 PD patients. In this study, we aim to evaluate the outcome of ICD behaviors in the same patient group.

Patients and methods

Among 33 patients with ICDs, 22 patients were included. Demographics, dopaminergic therapy and disease severity were compared between two time points (Time 1: time of diagnosis of ICD, Time 2: last visit) and between patients who recovered from ICDs and with ongoing ICDs. Types of antipsychotic and antidepressant medication were noted.

Results

Mean follow-up period was 43.2 months. At Time 2 mean dopamine agonist (DA) dose was significantly lower, levodopa dose and total UPDRS score was significantly higher. ICDs were dissolved in 16 patients (73%), but persisted in six (27%). In ICD(+) subgroup, DA doses in Time 1 was found significantly higher than ICD(−). However, age, PD severity, disease duration and levodopa dosage were similar. Fourteen patients were prescribed atypical antipsychotics and 13 antidepressants. In ICD(+) group, symptoms of ICDs were mainly increased libido and compulsive eating.

Conclusions

Although we studied a small number of patients the recovery from compulsive behaviors may be associated with the decrease in DA dosage and increase in levodopa. Furthermore, majority were given antipsychotic and/or antidepressant drugs. It is difficult to speculate which strategy could be more effective on the improvement of ICDs in such a small group. In patients who were on high doses of DA, ICDs could be persistent.

Keywords: Parkinson's disease, Impulse control disorders, Dopamine agonist, Levodopa, Follow-up

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The review of this paper was entirely handled by an Associate Editor, Jonathan Carr.

PII: S1353-8020(10)00044-1

doi:10.1016/j.parkreldis.2010.02.006

Parkinsonism & Related Disorders
Volume 16, Issue 5 , Pages 334-337, June 2010